

## TEKAMLO - (150MG;5MG, 150MG;10MG, 300MG;5MG, 300MG;10MG ; Tablet)

<b>Generic Name</b>	ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE	<b>Innovator</b>	Novartis
<b>Dosage</b>	150MG;5MG, 150MG;10MG, 300MG;5MG, 300MG;10MG ; Tablet	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	None	<b>Known Para IV Filers</b>	None
<b>Other ANDA developers</b>	None	<b>Tentative Approvals</b>	None
<b>Final Approvals</b>	None	<b>Generic Launches</b>	None
<b>Indication</b>	Tekamlo is a combination of aliskiren, a renin inhibitor, and amlodipine, a dihydropyridine calcium channel blocker, indicated for the treatment of hypertension, to lower blood pressure: ? As initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals. ? In patients not adequately controlled with monotherapy. ? As a substitute for its titrated components.		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.